Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that targeting androgen receptors with prostate cancer drugs ARN509 and finasteride induced remission and increased survival in a leukemia mouse model, suggesting a potential new treatment approach for acute myeloid leukemia.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

The new surgical technique for vitiligo is effective, safe, and cost-efficient.

This study found that intravenous high dose calcium infusions followed by high dose oral calcium effectively treated vitamin D dependent rickets type II, leading to complete biochemical and radiological healing and improved growth in two patients.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

This study found that bee venom accelerated the transition from the telogen to anagen phase in mice, increasing hair growth by day 14, and suggested that bee venom may enhance adipose-derived stem cell activity by upregulating growth factor secretion.

This study found that the purified compound VB1 from Vitex negundo seeds may reduce UVA-induced skin aging by targeting MAPK1 and demonstrated its potential in mice.

This study found that the evodiamine derivative 2-16 exhibited the highest antitumor activity and a broad spectrum of activity against various human cancer cell lines, with improved solubility.

In this report, a rare case of scalp arteriovenous fistula following hair transplantation was successfully treated using direct puncture embolization with n-butyl cyanoacrylate glue, demonstrating effective management of this condition.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study identified a specific SNP in the CACNB4 gene associated with a higher risk of chemotherapy-induced alopecia in breast cancer patients, which may help develop interventions to improve their quality of life.

This study investigated using baricitinib-loaded mesenchymal stem cell exosomes injected locally in an alopecia areata mouse model and found that this method improved hair regrowth better than baricitinib or exosomes alone, potentially offering a new therapeutic approach for treating alopecia areata.

A man developed a rare blood vessel connection on his scalp after hair transplants, which was successfully treated with surgery.

This case report describes the youngest known patient with viral-associated trichodysplasia of immunosuppression, where systemic valganciclovir therapy improved facial papule eruptions following cardiac transplantation.

This case report describes a 40-year-old woman with Birt-Hogg-Dubé syndrome diagnosed with multiple chromophobe renal cell carcinomas, highlighting the importance of recognizing associated dermatologic lesions for early intervention.

Vitamin E in the diet might help protect against hair loss caused by the chemotherapy drug doxorubicin in rabbits.

This study observed that Vitamin D receptor expression at protein and mRNA levels was significantly lower in the hair follicles of alopecia areata patients compared to healthy individuals.

This article highlights that early and high-dose corticosteroid therapy, along with immunosuppressive agents, is crucial for managing Vogt-Koyanagi-Harada disease, and emerging biological therapies may benefit refractory cases.

This research explores the integration of autologous regenerative therapy using adipose-derived stem cells and stromal vascular fraction in hair restoration surgery, aiming to improve follicular viability and enhance the environment around hair follicles, potentially offering benefits over traditional treatments like finasteride, minoxidil, and hair transplantation.

This study found that multidisciplinary group medical visits for patients with alopecia areata improved patient satisfaction, knowledge, and access to care at Lahey Hospital and Medical Center.

This report describes two cases where a viral vector COVID-19 vaccine was associated with the recurrence of cutaneous lymphoma conditions that had been in remission.

In this study, dogs with Vitamin A deficiency showed significant clinical and hematological improvement after receiving Vitamin A supplementation.

This study identified three new mutations in the VDR ligand-binding domain that may cause dysfunction, and noted that oral calcium and calcidol treatment was effective, but only one patient experienced hair growth.

This study characterized two siblings with hereditary vitamin D resistant rickets and a mutation in the vitamin D receptor, finding no immune-related disorders despite a defective T cell response to vitamin D.

In this study, researchers found no significant association between VDR gene polymorphisms and the susceptibility to alopecia areata, suggesting that these genetic variations may not play a role in the disease's development.

In this narrative case report, the authors discuss a patient recently diagnosed with an early-stage hematologic malignancy, highlighting her skepticism toward conventional medicine and preference for natural remedies over pharmaceutical treatments.

This observational study found that while 96.6% of patients using valproic acid showed the expected clinical response, over half experienced adverse reactions like weight gain, hair loss, and hepatotoxicity, highlighting the need for personalized treatment approaches to minimize these side effects.

This case report describes a 17-year-old boy with alopecia areata who had vitamin D deficiency and an incidentally discovered adrenal ganglioneuroma, with alopecia receding after vitamin D supplementation but later recurring despite normalized vitamin D and no tumor return.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.